| Status: Partially superseded | ||
AWMSG ADVICE PARTIALLY SUPERSEDED BY NICE GUIDANCE ISSUED JANUARY 2012. Refer to TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (which replaced NICE TA241) for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. Dasatinib (Sprycel®) is not recommended for use within NHS Wales for the treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myeloid leukaemia (LB-CML) with resistance or intolerance to prior therapy.
|
||
|
||
Medicine details |
||
| Medicine name | dasatinib (Sprycel®) | |
| Formulation | film-coated tablet | |
| Reference number | 102 | |
| Indication | Treatment of adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) and lymphoid blast chronic myeloid leukaemia (CML) with resistance or intolerance to prior therapy |
|
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Full | |
| Status | Partially superseded | |
| Advice number | 1407 | |
| NMG meeting date | 13/11/2007 | |
| AWMSG meeting date | 11/12/2007 | |
| Ratification by Welsh Government | 16/01/2008 | |
| Date of issue | 18/01/2008 | |
| NICE guidance | ||